Posted by Michael Wonder on 24 Feb 2024
Merck receives positive EU CHMP opinion for Keytruda (pembrolizumab) in combination with chemotherapy as neo-adjuvant treatment, then continued as monotherapy as adjuvant treatment, for the treatment of resectable NSCLC at high risk of recurrence
23 February 2024 - Opinion granted based on positive overall survival and event-free survival results from the Phase 3 KEYNOTE-671 trial.
Merck today announced that the EMA’s CHMP adopted a positive opinion recommending approval of Keytruda, Merck’s anti-PD-1 therapy, in combination with platinum-containing chemotherapy as neo-adjuvant treatment, then continued as a monotherapy as adjuvant treatment, for the treatment of resectable non-small cell lung cancer at high risk of recurrence in adults.
